Skip to content
  • Home
  • Journalists
    • Headlines
  • Community
    • Businesses
    • Jobs
    • Learning
    • Marketplace
  • Store
(@)

Trial of Controversial Alzheimer’s Drug Halted After Disappointing Results

Cassava Sciences said that its drug did not significantly reduce cognitive decline in 1,900 people with mild to moderate Alzheimer’s disease.

Teddy Rosenbluth
Author: Teddy Rosenbluth

Written by

Teddy Rosenbluth

in

Cassava Sciences Inc, Clinical Trials, Decisions and Verdicts, Falsification of Data, Regulation and Deregulation of Industry, Research, Securities and Commodities Violations, simufilam
←At the Brooklyn Academy, Musical Journeys Through Minefields
EV Projects to Get $13 Billion in Federal Loans→

More posts

  • Thriller ‘Games We Play’, With ‘Riverdale’ Star Casey Cott, Heads To AFM & Gets North American Release

  • Martha Stewart’s Charity Says It Doesn’t Serve Homeless After Costume Uproar

  • Judge rejects charges against former FBI agents who worked on the Hunter Biden case

  • Hulk Hogan’s Widow Sky Daily Insists She’s Not A Scientologist

About Us


Support Us

Trademark & Copyright 1998 – 2025 · MOSAEC

  • Facebook
  • Instagram
  • LinkedIn
  • YouTube